FDA Alert: Abacavir (marketed as Ziagen) and Abacavir. Alerts drugs.
[Posted 07/24/2008] FDA in the know healthcare professionals that sober and from time to time final hypersensitivity reactions (HSR) caused by abacavir remedy are significantly more plain in patients with a minute lenient leukocyte antigen (HLA) allele, HLA-B*5701. FDA reviewed figures from two studies that upkeep a testimonial for pre-therapy screening for the presence of the HLA-B*5701 allele and the choice of alternative treatment in positive subjects. Genetic tests for HLA-B*5701 are at and All patients should be screened for the HLA-B*5701 allele before starting or restarting healing with abacavir or abacavir-containing medications. Development of clinically suspected abacavir HSR requires present and imperishable discontinuation of abacavir remedial programme in All patients, including patients nullifying for HLA-B*5701.
Video:
Estimation article: here
